Eligible costs of rescEU medical aerial evacuation capacities, emergency medical team type 3 capacities, medical stockpiling, CBRN decontamination and CBRN stockpiling capacities
Implementing Decision (EU) 2019/570 is amended as follows:
(1)
in Article 2, paragraph 2 is amended as follows:
(a)
point (g) is replaced by the following:
‘(g)
chemical, biological, radiological, and nuclear (CBRN) decontamination capacities;’
(b)
the following point (h) is added:
‘(h)
chemical, biological, radiological, and nuclear (CBRN) stockpiling capacities.’;
(2)
Article 3a is replaced by the following:
‘Article 3a
Eligible costs of rescEU medical aerial evacuation capacities, emergency medical team type 3 capacities, medical stockpiling, CBRN decontamination and CBRN stockpiling capacities
All cost categories referred to in Annex Ia to Decision No 1313/2013/EU shall be taken into account when calculating the total eligible cost of rescEU capacities.’;
(3)
Articles 3b, 3c and 3f are deleted;
(4)
in Article 3e, paragraphs 3 and 4 are replaced by the following:
‘3. rescEU capacities referred to in points (c) to (h) of Article 2(2) shall be established with the objective of managing low probability risks with a high impact.
4. Where rescEU capacities referred to in points (c) to (h) of Article 2(2) are deployed under the Union Mechanism, Union financial assistance shall cover 100 % of the operational costs, pursuant to Article 23(4b) of Decision No 1313/2013/EU.’;
(5)
the Annex is amended in accordance with the Annex to this Decision.
This Decision is addressed to the Member States.
ANNEXSupplementary provisions
ANNEX
In the Annex to Implementing Decision (EU) 2019/570, the following Section 8 is added:
‘8. Stockpiling of chemical, biological, radiological and nuclear countermeasures and/or personal protective equipment aimed at assistance in the area of CBRN
Tasks
—
Stockpiling of CBRN countermeasures, comprising though not limited to, personal protective equipment, devices, laboratory supplies and logistics elements, as well as complementing and supporting other rescEU capacities, such as the CBRN decontamination and detection, surveillance and monitoring capacities for the purpose of preparedness and response to a CBRN event, including in response to cross-border threats to health ( 1 ) .
Capacities
—
Materials and systems ( 2 ) for decontaminating persons, infrastructure, buildings, vehicles, sensitive equipment and/or critical evidence, including from potential contamination with toxic industrial chemicals, recognised warfare agents, biological infectious agents (pathogens), biotoxins and radionuclides;
—
materials and devices necessary for detection, sampling, identification, surveillance and monitoring in order to keep safe an environment potentially exposed to CBRN agents;
—
materials and systems necessary for the containment of contamination and the management of waste and harmful by-products, including for contaminated water and clothes;
—
materials and systems necessary for fire containment and suppression in a CBRN event;
—
medical first line treatments, vaccines ( 3 ) , relevant generic rapid diagnostic kits and antidotes against CBRN agents (e.g. atropine and iodine tablets);
—
support and disposable materials such as discharges and consumables that are complementary for CBRN response, tools needed for maintenance and stand-by (e.g. air bottle filler), containers for polluted or contaminated material of different agents;
—
CBRN related logistics support elements such as, but not limited to, tents, logistic containers, equipment for transporting victims, and decontamination tents at hospitals;
—
personal protective equipment ( 4 ) and their regeneration or refill systems, if applicable, for individuals considered to be at risk ( 5 ) both as front line workers and population;
—
laboratory supplies, including sampling material, laboratory reagents, equipment and consumables ( 6 ) , to ensure laboratory capacity for CBRN-related risks;
—
body bags for CBRN contaminated fatalities;
—
any other items as needed, according to the identified risk.
Main components
—
Appropriate storage facilities in the Union ( 7 ) and adequate stockpiling monitoring system;
—
appropriate procedures ensuring the adequate packaging, transport and delivery of the products referred to under capacities, where needed;
—
appropriately trained personnel to oversee and handle the products referred to under capacities;
—
appropriate level of compliance with international standards and operation models, such as EU, WHO or NATO standards, including, where applicable, relevant Union legislation.
Deployment
—
Availability for departure maximum 12 hours after the acceptance of the offer.
( 1 ) As defined in Decision No 1082/2013/EU.
( 2 ) Such as PPE regeneration and refill systems.
( 3 ) The quality requirements for vaccines should be those under point 6 above.
( 4 ) Covering the following categories: (i) eye protection; (ii) hand protection; (iii) respiratory protection; (iv) body protection; and (v) foot protection, in different sizes.
( 5 ) See footnote 2.
( 6 ) This may include, but is not limited to, RT-PCR reagents, such as enzymes, RNA extraction reagents, RNA extraction machine time, PCR machine time, primer and probe reagents, positive control reagents, PCR laboratory consumables (e.g. tubes and plates) and disinfectants.
( 7 ) For the purposes of the logistics of storage facilities, “in the Union” encompasses the territories of Member States and Participating States of the Union Civil Protection Mechanism.’
